Entrar Registro gratuito

Last updated: 22 March 2024 at 5:03pm EST

Lawrence Kenyon Net Worth




The estimated Net Worth of Lawrence A Kenyon is at least $2.04 Milhão dollars as of 20 April 2021. Mr. Kenyon owns over 10,000 units of Outlook Therapeutics Inc stock worth over $133,050 and over the last 8 years he sold OTLK stock worth over $40,648. In addition, he makes $1,863,900 as President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, e Director at Outlook Therapeutics Inc.

Mr. Kenyon OTLK stock SEC Form 4 insiders trading

Lawrence has made over 4 trades of the Outlook Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of OTLK stock worth $18,300 on 20 April 2021.

The largest trade he's ever made was selling 26,165 units of Outlook Therapeutics Inc stock on 22 December 2017 worth over $29,566. On average, Lawrence trades about 4,329 units every 110 days since 2016. As of 20 April 2021 he still owns at least 18,926 units of Outlook Therapeutics Inc stock.

You can see the complete history of Mr. Kenyon stock trades at the bottom of the page.





Lawrence Kenyon biography

Lawrence A. Kenyon serves as President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director of the Company. Mr. Kenyon has served as the Company’s CFO, Treasurer and Corporate Secretary since September 2015 and as Interim CEO since June 2018. Prior to that, from February 2014 to September 2015, Mr. Kenyon served as the CFO of Arno Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics for cancer and other life threatening diseases, and also as Chief Operating Officer (“COO”) from July 2014 to September 2015. From December 2011 to March 2013, Mr. Kenyon served as the Interim President & CEO, CFO and Secretary of Tamir Biotechnology, Inc., a publicly held biopharmaceutical company engaged in the development of oncology and anti-infective therapeutics. Prior to that, from December 2008 to July 2010, Mr. Kenyon was the Executive Vice President, Finance and, commencing in March 2009, the CFO of, Par Pharmaceutical Companies, Inc., a publicly held generic and branded specialty pharmaceutical company, or Par. Prior to joining Par, Mr. Kenyon was the CFO and Secretary of Alfacell Corporation, or Alfacell, from January 2007 through February 2009 and also served at various times during this period as Alfacell’s Executive Vice President, COO and President, and was a member of Alfacell’s board of directors from November 2007 to April 2009. Prior to joining Alfacell, Mr. Kenyon served as the Executive Vice President, CFO and Corporate Secretary at NeoPharm, Inc., a publicly traded biopharmaceutical company, from 2000 to 2006. Mr. Kenyon received a B.A. in Accounting from the University of Wisconsin-Whitewater and is a Certified Public Accountant in Illinois.

What is the salary of Lawrence Kenyon?

As the President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, e Director of Outlook Therapeutics Inc, the total compensation of Lawrence Kenyon at Outlook Therapeutics Inc is $1,863,900. There are no executives at Outlook Therapeutics Inc getting paid more.



How old is Lawrence Kenyon?

Lawrence Kenyon is 54, he's been the President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, e Director of Outlook Therapeutics Inc since 2018. There are 9 older and 4 younger executives at Outlook Therapeutics Inc. The oldest executive at Outlook Therapeutics Inc is Ralph H. Thurman, 72, who is the Independent Exec. Chairman.

What's Lawrence Kenyon's mailing address?

Lawrence's mailing address filed with the SEC is C/O OUTLOOK THERAPEUTICS, INC., 485 ROUTE 1 SOUTH, BLDG F, SUITE 320, ISELIN, NJ, 08830.

Insiders trading at Outlook Therapeutics Inc

Over the last 6 years, insiders at Outlook Therapeutics Inc have traded over $1,453,842 worth of Outlook Therapeutics Inc stock and bought 29,698,365 units worth $33,411,235 . The most active insiders traders include Pte Ltd.Pillai Arun Kumar S..., Ghiath M.Gms Ventures & Inv..., eVentures Llc Syntone. On average, Outlook Therapeutics Inc executives and independent directors trade stock every 43 days with the average trade being worth of $11,985,869. The most recent stock trade was executed by Ventures Llc Syntone on 15 April 2024, trading 714,286 units of OTLK stock currently worth $5,021,431.



What does Outlook Therapeutics Inc do?

overview oncobiologics is a pure-play complex biosimilar company focused on technically challenging and commercially attractive monoclonal antibodies (mabs), in the therapeutic areas of immunology and oncology. our strategy is to cost-effectively develop technically challenging biosimilars on an accelerated timeline, which we believe is fundamental to our success and positions us to be a leading biosimilar company. we have leveraged our team’s biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our biosymphony™ platform. oncobiologics’ platform addresses the numerous complex technical and regulatory challenges in developing and commercializing mab biosimilars. pipeline oncobiologics is actively working on eight biosimilar candidates. the company’s most advanced assets, ons-3010 (a biosimilar of humira®) and ons-1045 (a biosimilar of avastin®) have both successfully completed phase i trials and phase 3 t



What does Outlook Therapeutics Inc's logo look like?

Outlook Therapeutics Inc logo

Complete history of Mr. Kenyon stock trades at Outlook Therapeutics Inc

Data
#
Companhia
 Acionista maioritário
Trans.
Transação
 Ações Preço por ação Preço total Ações após Fonte
20 Apr 2021 OTLK Outlook Therapeutics Inc Lawrence A Kenyon
Diretor Financeiro
 Comprar 10,000 $1.83 $18,300
20 Apr 2021
18,926 ↗
18 Sep 2019 OTLK Outlook Therapeutics Inc Lawrence A Kenyon
Diretor Financeiro
 Venda 1,350 $1.70 $2,295
18 Sep 2019
80,863 ↗


Outlook Therapeutics Inc executives and stock owners

Outlook Therapeutics Inc executives and other stock owners filed with the SEC include: